Home Page > The Entire Public Record By Date 108th > By Subject > Oversight

Oversight

The Public Record for the 108th Congress

This is a list of public information regarding oversight issues released in the 108th Congress by the Committee on Energy and Commerce Democrats. The information is listed by date.

If you require information that was available on this website for a previous Congress, please see our archives page.

» News Releases	View »
» Letters	View »
» Statements	View »
» Staff Reports	View »
» Dear Colleague Letters	View »

News Releases

July 6, 2004	Statement by Congressman John D. Dingell regarding the Inspector General investigation into allegations against former Centers for Medicare and Medicaid Services Administrator Tom Scully
September 24, 2003	"GAO: Security At Nuclear Reactors Needs Strengthening"
April 2, 2003	"Tauzin, Dingell Release Report on Nation's Critical Infrastructure"
Return to Top ^

Letters on Current Issues

December 21 , 2004	to Mr. David Balland, Associate Commissioner for Medicaid and CHIP, Texas Health and Human Services Commission, asking additional questions for the record for the Subcommittee on Oversight and Investigations December 7, 2004, hearing entitled "Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much"
December 21 , 2004	to Mr. Paul Rinehart, Medicaid Director for the State of Michigan, asking additional questions for the record for the Subcommittee on Oversight and Investigations December 7, 2004, hearing entitled "Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much"
December 17 , 2004	from Chairman Barton and Ranking Member Dingell to Dr. Hank McKinnell, Chairman and CEO of Pfizer Inc. regarding the Committee's examination of potential cardiovascular safety issues surrounding COX-2 inhibitor drugs, such as Vioxx, Celebrex, and Bextra
December 9 , 2004	from Chairman Barton and Ranking Member Dingell to HHS Secretary Thompson with recommendations regarding the Administration's plan to reform FDA's regulation of drug safety
November 23 , 2004	to Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs, FDA, related to the Committee's examination of issues surrounding the recent withdrawal of Vioxx
November 23 , 2004	to Mr. Raymond Gilmartin, Chairman, Merck & Co., Inc. regarding the Committee's examination of issues surrounding the recent withdrawal of Vioxx
November 22 , 2004	to NIH Director Zerhouni, regarding the Committee's examination of the NIH's management and oversight of federally funded research
November 18 , 2004	to HHS Secretary Thompson requesting information related to the Committee's investigation into the recent loss of nearly half of the flu vaccine needed by the United States
November 18 , 2004	to Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs, FDA, requesting information related to the Committee's investigation into the recent loss of nearly half of the flu vaccine needed by the United States
November 18 , 2004	to Howard Pien, President, CEO and Chairman of the Board, Chiron Corporation requesting information related to the Committee's investigation into the recent loss of nearly half of the flu vaccine needed by the United States
October 27, 2004	to FCC Chairman Powell regarding changes made by the FCC that has resulted in withholding of hundreds of millions of dollars in commitments for Internet funding for schools, libraries, and rural healthcare facilities under the E-rate program See attachments to letter: Attachment 1, Attachment 2 Print version of attachments: Attachment 1, Attachment 2
October 25, 2004	to Mr. George McDonald, Vice President, Schools and Libraries Division, Universal Service Administrative Company
October 22, 2004	to David D. Smith, President and CEO, Sinclair Broadcast Group, Inc.
October 21, 2004	to Comptroller General Walker asking the GAO to investigate the apparent misuse or mishandling of intelligence expertise at the Department of Energy in the year 2002
October 21 , 2004	to Daniel Levinson, Acting Inspector General, Department of Health and Human Services requesting that the IG's office provide a response to a Dec. 22, 2003, letter from the Hon. John D. Dingell regarding a waiver of HHS's code of ethics for Thomas A. Scully
September 22, 2004	to Comptroller General Walker providing GAO with the July 26, 2004, response of the U.S. Drug Enforcement Agency to the Hon. John D. Dingell's May 5th letter, for use in their ongoing work on the entry of controlled substances into this country through mail and consignment delivery
June 22, 2004	to Senate Majority Leader Frist and Speaker Hastert from Senate Democratic Leader Daschle, House Democratic Leader Pelosi, Rep. Dingell, and ten other Congressional leaders regarding the failure of the House and Senate to investigate the Administration’s withholding of Medicare cost estimates from Congress See also Letter to President Bush where the Members ask the President to provide complete answers to straightforward questions on his role in the matter
June 4, 2004	to NIH Director Zerhouni asking several additional questions for the record regarding the May 18, 2004, Subcommittee on Oversight and Investigations hearing entitled "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
June 4, 2004	to Dr. Raymond S. Kington, NIH Deputy Director, asking several additional questions for the record regarding the May 18, 2004, Subcommittee on Oversight and Investigations hearing entitled "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
June 4, 2004	to Dr. Harold Varmus, President and CEO, Memorial Sloan-Kettering Cancer Center, asking several additional questions for the record regarding the May 18, 2004, Subcommittee on Oversight and Investigations hearing entitled "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
June 3, 2004	to Mr. Edgar M. Swindell, Associate General Counsel of HHS's Ethics Division, asking several additional questions for the record regarding the May 18, 2004, Subcommittee on Oversight and Investigations hearing entitled "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
June 3, 2004	to Ms. Marilyn L. Glynn, Acting Director, U.S. Office of Government Ethics, asking several additional questions for the record regarding the May 18, 2004, Subcommittee on Oversight and Investigations hearing entitled "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
June 2, 2004	to DOE Deputy Secretary McSlarrow asking several additional questions for the record regarding the May 11, 2004, Subcommittee on Oversight and Investigations hearing entitled "DOE Nuclear Security: What Are the Challenges and What's Next?"
May 28, 2004	to Comptroller General Walker from Reps. Dingell and Capps asking GAO to investigate the decision by the FDA to find "non-approvable" an application to make emergency contraception available over the counter without a prescription
March 5, 2004	to Dr. Marv Shepherd, Director, Center for Pharmacoeconomic Studies, Drug Dynamics Institute, from Rep. Dingell and Senator Coleman asking for information related to the issue of imported pharmaceuticals
February 24, 2004	to DEA Administrator Tandy asking the DEA to take action in regard to the illegal sale and distribution of controlled substances purchased through the Internet
February 13, 2004	to President Bush regarding the accuracy of statements made in his 2002 State of the Union address on potential threats to U.S. nuclear power plants
December 22, 2003	to Ms. Dara Corrigan, Acting Principal Deputy Inspector General, Department of Health and Human Services (HHS), asking for an examination of whether HHS Secretary Thompson's waiver of the code of ethics for Mr. Thomas Scully to allow Mr. Scully to discuss prospective jobs with organizations which had substantial financial interests in legislative and regulatory matters pending at the Centers for Medicare and Medicaid Services (CMS) while he headed CMS was a violation of those regulations
November 13, 2003	to Comptroller General Walker asking the GAO to conduct a review of existing laws, regulations, and procedures related to the Committee's investigation of imported pharmaceuticals
October 20, 2003	to Customs Commissioner Bonner, FDA Commissioner McClellan, and DEA Administrator Tandy regarding the Committee's investigation of the sale and distribution of prescription drugs entering the U.S. from foreign sources
September 12, 2003	to Office of Management and Budget Director Bolten requesting justification for the Administration request for an additional $2.1 billion to rebuild Iraq's oil fields
July 14, 2003	to FDA Commissioner McClellan regarding the Committee's investigation into the safety and efficacy of pharmaceuticals imported into the U.S.
June 4, 2003	to FDA Commissioner McClellan regarding the investigation of imported pharmaceuticals
April 8, 2003	letters from Reps. Dingell and Waxman asking GAO to investigate Defense Department contracts awarded to Halliburton over the past two years and to review the process by which the Administration has signed or intends to sign contracts with private firms for development work in Iraq Letter to GAO on Halliburton contracts Letter to GAO on Iraq contracts
March 25, 2003	to Ms. Edita Kaye, President, The Skinny Pill, threatening to subpoena the firm unless it supplies the requested information on the “Skinny Pill for Kids” by Friday, April 4, 2003
March 25, 2003	to Mr. Dennis Gay, President and CEO, Basic Research LLC, regarding a dietary supplement Basic Research LLC is marketing called "PediaLean"
March 25, 2003	to DEA Acting Administrator Brown requesting detailed information and a private briefing on the safety, proliferation and potential loopholes associated with “pro-steroid” and “precursor steroid” products
March 25, 2003	to FDA Commissioner McClellan requesting detailed information and a private briefing on the safety, proliferation and potential loopholes associated with “pro-steroid” and “precursor steroid” products
March 24, 2003	to Homeland Security Secretary Ridge, OMB Director Daniels, House Appropriations Committee Chairman Young, and Senate Appropriations Committee Chairman Stevens calling for additional radiation portal monitors to be installed at various points of entry along America’s border
February 28, 2003	to Mr. Robert Chinery, President of Cytodyne Technologies, requesting an examination of Xenadrine RFA-1, an ephedra-containing supplement that Cytodyne Tech. manufactures
Return to Top ^

Statements

September 15, 2004	Full Committee Markup to consider H.Res. 745, a resolution of inquiry regarding the Cheney Energy Task Force
September 9, 2004	Subcommittee on Oversight and Investigations hearing on "Publication and Disclosure Issues in Anti-depressant Pediatric Clinical Trials"
September 9, 2004	House Floor Debate on the Stark Amendment to H.R. 5006
July 22, 2004	Subcommittee on Oversight and Investigations hearing on "Problems with the E-rate Program: Waste, Fraud, and Abuse Concerns in the Wiring of our Nation's Schools to the Internet"
June 22, 2004	Subcommittee on Oversight and Investigations Hearing on "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
June 17, 2004	Subcommittee on Oversight and Investigations Hearing on "Problems With E-Rate Program: Waste, Fraud, and Abuse Concerns in the Wiring of our Nation's Schools to the Internet"
June 16, 2004	Subcommittee hearing on "Parents Be Aware: Health Concerns About Dietary Supplements for Overweight Children"
May 12, 2004	Subcommittee hearing on "NIH Ethics Concerns: Consulting Arrangements and Outside Awards"
March 4, 2004	Subcommittee hearing on "A Review of Security at DOE Nuclear Facilities and the Implementation of the Revised Design Basis Threat"
March 4, 2004	Health Subcommittee hearing on "Prescription Drug Monitoring Strategies to Promote Treatment and Deter Prescription Drug Abuse"
July 24, 2003	Floor statement on the "Pharmaceutical Market Access Act of 2003"
July 23, 2003	Subcommittee hearing on "Issues Relating to Ephedra-containing Dietary Supplements"
July 17, 2003	Subcommittee hearing on "A Review of DOE's Radioactive High-level Waste Cleanup Program"
June 24, 2003	Subcommittee hearing on "A System Overwhelmed: The Avalanche of Imported, Counterfeit, and Unapproved Drugs Into The U.S."
June 3, 2003	Subcommittee hearing on "Assessing Initiatives to Increase Organ Donation"
May 1, 2003	Subcommittee hearing on "A Review of the University of California's management contract for Los Alamos National Laboratory"
February 26, 2003	Subcommittee hearing entitled "Procurement and Property Mismanagement and Theft at Los Alamos National Laboratory"
Return to Top ^

Staff Reports

June 24, 2003	Committee Staff Memorandum reporting on Imported Pharmaceutical Safety -- Miami International Mail-Branch Facility Visit in March 2003
Return to Top ^

Dear Colleague Letters

(Letters to Fellow House Members on Current Legislation) [These letters are in PDF format. You will need Adobe Acrobat to read them. If this format will not work for you, please contact our office for a copy.]
July 23, 2003	"Imported Prescription Drugs Don't Need to Poison to be Dangerous"
Return to Top ^

To read these documents, you must have Adobe Acrobat Reader software installed on your computer. Click on the icon below to download this software for free if you do not have it already installed.